RVL Pharmaceuticals plc

OTCPK:RVLP.Q Stok Raporu

Piyasa değeri: US$111.0

RVL Pharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

RVL Pharmaceuticals does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-21,348,648.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi-21,348,648.6%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if RVLP.Q's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if RVLP.Q's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

RVL Pharmaceuticals Piyasaya Karşı Temettü Getirisi
RVLP.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (RVLP.Q)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Pharmaceuticals)2.3%
Analist tahmini (RVLP.Q) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate RVLP.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate RVLP.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate RVLP.Q's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as RVLP.Q has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin